NCT05256225 2026-03-18
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
National Cancer Institute (NCI)
Phase 3 Recruiting
Clinical Trials
11 trialsNCT01042379 2026-03-13
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT07416409 2026-02-18
Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer
Deraya University
Completed
NCT02693535 2026-02-13
TAPUR
American Society of Clinical Oncology
Phase 2 Recruiting
NCT05150691 2026-01-28
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
Phase 1/2 Recruiting
NCT05722886 2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT04341181 2025-07-25
ProTarget
Rigshospitalet, Denmark
Phase 2 Recruiting
NCT02091141 2024-07-23
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
Genentech, Inc.
Phase 2 Completed
NCT05912062 2023-09-29
BiOnHER
Institut Català d'Oncologia
Unknown
NCT00027027 2015-07-27
Safety Study of rhuMAb 2C4 to Treat Advanced Solid Tumors
Genentech, Inc.
Phase 1 Completed
NCT00096993 2015-06-10
A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Genentech, Inc.
Phase 2 Completed